Signal crosstalk in molecular targeted therapy for prostate cancer

• Project/Area Number: 24592412
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Jikei University School of Medicine
• Principal Investigator: KIYOTA Hiroshi 東京慈恵会医科大学, 医学部, 教授 (30153240)
• Co-Investigator(Kenkyū-buntansha): KIMURA Takahiro 東京慈恵会医科大学, 泌尿器科, 講師 (00307430)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000); Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000); Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
• Keywords: 前立腺癌

Outline of Final Research Achievements

The aim of the study was to elucidate the signal crosstalk in prostate cancer xenograft model, JDCaP. JDCaP expressed typical markers of prostate cancer such as PSA, AR and ERG. Several pathways including AR and tyrosine kinase-akt were activated in JDCaP. IN vivo xenograft model, both anti-androgen drug, bicalutamide and throsine kinase inhibitor, sunitinib showed anti-tumor effect. However, sunitinib inhibited tyrosine kinase pathway but activated AR pathway, which suggested signal crosstalk of both pathways.